Standardization of HER2 testing:: results of an international proficiency-testing ring study

被引:108
作者
Dowsett, Mitch [1 ]
Hanna, Wedad M.
Kockx, Mark
Penault-Llorca, Frederique
Rueschoff, Josef
Gutjahr, Thorsten
Habben, Kai
van de Vijver, Marc J.
机构
[1] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England
[2] Univ Toronto, Dept Pathol Anat, Toronto, ON, Canada
[3] Histogenex, Antwerp, Belgium
[4] Ctr Jean Perrin, Dept Pathol, Clermont Ferrand, France
[5] Klinikum Kassel, Inst Pathol, Kassel, Germany
[6] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[7] Roche Diagnost GmbH, Penzberg, Germany
[8] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
关键词
breast cancer; HER2; quality control; trastuzumab;
D O I
10.1038/modpathol.3800774
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Human epidermal growth factor receptor 2 (HER2) positivity in breast cancer is a prognostic factor regarding tumor aggressiveness and a predictive factor for response to trastuzumab (Herceptins). Early and accurate HER2 testing of all breast cancer patients at primary diagnosis is essential for optimal disease management. Routine HER2 tests, such as immunohistochemistry and fluorescence in situ hybridization (FISH), are subject to interlaboratory variation, and validation by laboratory proficiency testing is important to improve standardization. This study compared immunohistochemistry and FISH testing between five international pathology reference centers. Each center evaluated 20 immunohistochemistry and 20 FISH breast cancer specimens in five testing rounds. In each round, one center selected two sets of four different invasive tumor specimens ( set A for immunohistochemistry and set B for FISH) and sent samples to the other four centers in a blinded manner, while retaining samples for its own evaluation. Results were analyzed by an independent coordinator. With immunohistochemistry, there were no differences between the five centers for any of the specimens at the level of diagnostic decision (positive or negative HER2 status). However, differences between laboratories were observed in immunohistochemistry scoring. Of the 20 specimens, four were scored as negative (0/1+) and five as positive (3+) in all centers; eight were negative or equivocal (2+), and three positive or equivocal. After FISH retesting of nine of the 11 equivocal immunohistochemistry cases, consensus was achieved in 15 of 18 (83%) specimens. FISH analysis of set B specimens resulted in consensus between centers in 16 of 20 (80%) specimens (six negative and 10 positive). All four discordant FISH specimens were scored as having HER2:CEP17 ratios within the range 1.7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures.
引用
收藏
页码:584 / 591
页数:8
相关论文
共 35 条
[1]  
American Cancer Society, 2006, BREAST CANC FACTS FI
[2]  
[Anonymous], CLIN PRACT GUID ONC
[3]   Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J].
Arnould, L ;
Denoux, Y ;
MacGrogan, G ;
Penault-Llorca, F ;
Fiche, M ;
Treilleux, I ;
Mathieu, MC ;
Vincent-Salomon, A ;
Vilain, MO ;
Couturier, J .
BRITISH JOURNAL OF CANCER, 2003, 88 (10) :1587-1591
[4]   Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule [J].
Baselga, J ;
Carbonell, X ;
Castañeda-Soto, NJ ;
Clemens, M ;
Green, M ;
Harvey, V ;
Morales, S ;
Barton, C ;
Ghahramani, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2162-2171
[5]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[6]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[7]  
BILOUS M, 2004, EBCC HAMB GERM 16 20
[8]   Cancer incidence and mortality in Europe, 2004 [J].
Boyle, P ;
Ferlay, J .
ANNALS OF ONCOLOGY, 2005, 16 (03) :481-488
[9]  
Carlson Robert W, 2005, J Natl Compr Canc Netw, V3 Suppl 1, pS7
[10]  
Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1